Skip to main content
Premium Trial:

Request an Annual Quote

R. Mark Adams, Gavin MacBeath, Aneil Mallavarapu

R. Mark Adams has been promoted to principal from senior associate at Booz Allen Hamilton.
Adams is head of the consulting firm’s biomedical informatics group and program manager for the National Cancer Institute’s Cancer Biomedical Informatics Grid project, caBIG. Booz Allan has been a caBIG contractor since the program was launched.
Adams joined Booz Allen Hamilton in 2003 with 15 years of experience in bioinformatics, where he has designed and implemented large-scale informatics systems, including regulated systems for use in clinical trials. Prior to joining the firm, he served as director of bioinformatics at Nuvelo.

The Council for Systems Biology in Boston has awarded its 2008 Innovation awards to two Harvard University scientists — Aneil Mallavarapu and Gavin MacBeath — according to a Harvard Medical School newsletter.
CBS2 is a Boston-area association of academic, clinical, and industrial groups active in the areas of systems biology and systems pharmacology and is based in Harvard Medical School’s Department of Systems Biology.
Mallavarapu, the recipient of the Merrimack-CSB2 Prize, is a senior research scientist in the medical school’s Virtual Cell Program. CSB2 recognized him for his work on little b, an open-source LISP-based language for building modular, shareable, and scalable models of biological systems.
MacBeath, the recipient of the Pfizer-CSB2 Prize, is an associate professor of chemistry and chemical biology at Harvard. He was recognized for his development of new protein microarray methods applicable to the study of signal transduction, disease, and targeted therapy in humans.
The Merrimack prize is awarded annually to a young scientist for “exceptional contributions to the development and application of innovative modeling and computational methods as judged by technical quality, broad utility and fundamental theoretical insight,” according to CSB2, while the Pfizer prize recognizes “exceptional contributions to the development and implementation of new measurement methods characterized by analytic rigor, broad potential, and innovative approach.”

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.